Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 2.73B |
| Revenue (ttm) | 35.47M |
| Net Income (ttm) | -470.79M |
| Shares Out | 123.90M |
| EPS (ttm) | -4.24 |
| PE Ratio | n/a |
| Forward PE | 111.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,944,383 |
| Open | 22.34 |
| Previous Close | 22.08 |
| Day's Range | 21.65 - 22.76 |
| 52-Week Range | 20.67 - 40.89 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 51.00 (+131.19%) |
| Earnings Date | May 9, 2024 |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical ... [Read more]
Financial Performance
In 2023, ARWR's revenue was $240.74 million, a decrease of -1.03% compared to the previous year's $243.23 million. Losses were -$205.28 million, 16.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ARWR stock is "Strong Buy." The 12-month stock price forecast is $51.0, which is an increase of 131.19% from the latest price.
News
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is ho...
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This mi...
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Marke...
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage...
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss i...
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB...
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investiga...
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 30, 2024, the C...
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran av...
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dos...
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual...
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023. The Company is ...
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discu...
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering...
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock,...
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO...
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conferenc...
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023. The company is hosting a con...
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO...
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Piper Sandler 35th An...
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m. ET to disc...
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3...
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Jefferies London Heal...
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of ...
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2023 Annual Northeast ...